Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Warning Time and Patient-Selected Goals Study of Kentera for Overactive Bladder
2005-005009-41Phase 4Completed
- Sponsor
- King's College Hospital
- Start
- Nov 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of oxybutynin in overactive bladder (OAB), sponsored by King's College Hospital. Primary endpoint: Achievement of patient-selected goals. Started Nov 2005; status: completed.
02
Drugs
oxybutynin
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on 2005-005009-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005009-41.